Minimal Residual Disease (MRD) – Cost vs Benefit

Detection of Minimal Residual Disease (MRD) is  becoming more important in different fields of hematology including Multiple Myeloma. Over the past decades we’ve been able to improve the sensitivity of detecting minimal levels of MRD through innovations in molecular biology. But should MRD always be treated?  Will it give a better outcome for the patient? And do the benefits outweigh the costs?”

Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Dr Fredrik Schjesvold, head of the Oslo Myeloma Center.

MAT-BE-2200983 (1.0) 12 2022
Medipodcast

Medipodcast

Biographical Info

You may also be interested in these contents :

Welcome back !

Login to your account below

Create New Account!

Fill the forms bellow to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.

Retrieve your password

Please enter your username or email address to reset your password.

Add New Playlist

Create New Account!

Fill the form below to register

You already have an account ? Login
-
00:00
00:00
Update Required Flash plugin
-
00:00
00:00